08HH Stock Overview
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. More details
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 4/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 1/6 |
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥1.78 |
52 Week High | CN¥2.32 |
52 Week Low | CN¥1.33 |
Beta | 0.72 |
11 Month Change | 2.13% |
3 Month Change | n/a |
1 Year Change | -12.99% |
33 Year Change | -60.47% |
5 Year Change | -29.00% |
Change since IPO | -32.89% |
Recent News & Updates
Recent updates
Shareholder Returns
08HH | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | 0% | -0.1% | 3.2% |
1Y | -13.0% | -13.3% | 9.7% |
Return vs Industry: 08HH matched the German Pharmaceuticals industry which returned -13.3% over the past year.
Return vs Market: 08HH underperformed the German Market which returned 9.7% over the past year.
Price Volatility
08HH volatility | |
---|---|
08HH Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 5.9% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 11.5% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 08HH's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 08HH's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1994 | 39,309 | Deyong Wen | www.fosunpharma.com |
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. The company’s product pipeline includes HLX15, a recombinant anti-CD38 human monoclonal antibody injection for treatment of multiple myeloma; HLX13, an anti-CTLA-4 human monoclonal antibody for the treatment of melanoma, renal cell carcinoma, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, malignant pleural mesothelioma, and esophageal squamous cell cancer; SZEY-2108 for the treatment of carbapenem resistant enterobacteriaceae (CRE) infection; XH-S003 for the treatment of IgA nephropathy and other glomerular diseases; HLX43, an antibody-drug for the treatment of metastatic solid tumors; XS-03 for the treatment of RAS-mutated advanced solid tumor; OP0595, a nacubactam for the treatment of aerobic gram-negative bacteria; XH-S002 for the treatment of ischemic stroke and transient ischemic attack which are in Phase I; HLX26, anti-LAG-3 humanized monoclonal antibody injection for the treatment of metastatic colorectal cancer; FCN-338 for the treatment of myeloid malignancies; FCN-159 for the treatment of langerhans cell histiocytosis; HLX208, a BRAF V600E inhibitor for the treatment of non-small cell lung cancer which are in phase II; FS-1502, a HER2 humanized monoclonal antibody-monomethyl auristatin F injection for the treatment of HER2-positive locally advanced or metastatic breast cancer; FCN-159 for the treatment of neurofibromatosis; ET-26, a methoxyetomidate hydrochloride for the treatment of general anesthesia which are in phase III.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Fundamentals Summary
08HH fundamental statistics | |
---|---|
Market cap | €8.22b |
Earnings (TTM) | €275.28m |
Revenue (TTM) | €5.42b |
33.2x
P/E Ratio1.7x
P/S RatioIs 08HH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
08HH income statement (TTM) | |
---|---|
Revenue | CN¥41.61b |
Cost of Revenue | CN¥21.83b |
Gross Profit | CN¥19.78b |
Other Expenses | CN¥17.67b |
Earnings | CN¥2.11b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.79 |
Gross Margin | 47.55% |
Net Profit Margin | 5.08% |
Debt/Equity Ratio | 55.0% |
How did 08HH perform over the long term?
See historical performance and comparison